KalVista Pharmaceuticals (KALV) Change in Account Payables (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Change in Account Payables of $2.5 million for Q3 2025, up 67.11% on a YoY basis from $1.5 million in Q3 2024, and up 280.32% sequentially from -$1.4 million in Q2 2025.
KalVista Pharmaceuticals (KALV) Change in Account Payables (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Change in Account Payables data on file, last reported at $2.5 million in Q3 2025.
- For the quarter ending Q3 2025, Change in Account Payables rose 67.11% year-over-year to $2.5 million; the trailing twelve-month figure through Jul 2025 stood at -$3.2 million (down 156.7% YoY), and the FY2025 full-year result was -$5.0 million, down 215.07% from the prior year.
- Change in Account Payables grew to $2.5 million in Q3 2025, from -$1.4 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $6.1 million in Q2 2024 to a low of -$5.9 million in Q4 2024.
- A 5-year average of $198777.8 and a median of $81500.0 in 2023 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 1290.74% in 2024, while the deepest fall reached 10754.55% in 2024.
- Tracing KALV's Change in Account Payables over 5 years: stood at $1.7 million in 2021, then tumbled by 64.7% to $597000.0 in 2022, then slumped by 90.79% to $55000.0 in 2023, then sank by 10754.55% to -$5.9 million in 2024, then jumped by 142.83% to $2.5 million in 2025.
- Business Quant data shows KALV's Change in Account Payables at $2.5 million in Q3 2025, -$1.4 million in Q2 2025, and -$5.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 2.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 2.51 Mn |
| Jul 31, 2025 | 2.51 Mn |
| Apr 30, 2025 | -1.39 Mn |
| Apr 30, 2025 | -1.39 Mn |
| Oct 31, 2024 | -5.86 Mn |
| Oct 31, 2024 | -5.86 Mn |
| Jul 31, 2024 | 1.50 Mn |
| Jul 31, 2024 | 1.50 Mn |
| Apr 30, 2024 | 6.10 Mn |
| Apr 30, 2024 | 6.10 Mn |
| Jan 31, 2024 | -1.94 Mn |
| Jan 31, 2024 | -1.94 Mn |
| Oct 31, 2023 | 55,000.00 |
| Oct 31, 2023 | 55,000.00 |
| Jul 31, 2023 | 108,000.00 |
| Jul 31, 2023 | 108,000.00 |
| Apr 30, 2023 | 3.02 Mn |
| Apr 30, 2023 | 3.02 Mn |
| Jan 31, 2023 | -1.83 Mn |
| Jan 31, 2023 | -1.83 Mn |